oxazolidin-2-one has been researched along with Hepatocellular Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhadauria, AS; Bhattachariya, B; Chakraborti, S; Gosipatala, SB; Kumar R, V; Kumar, D; Kumar, P; Kumar, U; Maity, B; Maurya, V; Pramanik, A; Saha, B; Saha, S; Singh, AK | 1 |
| Sato, M; Stammer, CH | 1 |
2 other study(ies) available for oxazolidin-2-one and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Zolmitriptan attenuates hepatocellular carcinoma via activation of caspase mediated apoptosis.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cytokines; Disease Models, Animal; Glutathione; Lipids; Liver; Liver Neoplasms; Male; Nitric Oxide Synthase Type II; Oxazolidinones; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Tryptamines | 2019 |
5-Carboxamido-4-amino-3-isoxazolidone, and asparagine analogue.
Topics: Animals; Antineoplastic Agents; Aspartate-Ammonia Ligase; Carcinoma, Hepatocellular; Isoxazoles; Leukemia L1210; Leukemia, Experimental; Liver Neoplasms; Mice; Neoplasms, Experimental; Oxazoles; Oxazolidinones | 1978 |